Bulletin of Experimental Treatments for AIDS (BETA), published by the San Francisco AIDS Foundation, is one of the most comprehensive HIV treatment publications, with hundreds of in-depth articles.

Published in the Bulletin of Experimental Treatments for AIDS March 1997 issue, by the San Francisco AIDS Foundation.

BETA
March 1997 Table of Contents

Main Page

Contact Us
beta@sfaf.org

 

Types and names of Antiretroviral Drugs

Table assembled by Harvey S. Bartnof, MD, for the San Francisco AIDS Foundation


Nucleoside Analogs (NA)

Abbrev: AZT
Generic name: zidovudine
Brand name: Retrovir
Adult dose: 200 mg q 8

Abbrev.: ddI
Generic name: didanosine
Brand name: Videx
Adult dose: 167-375 mg q 12

Abbrev.: ddC
Generic name: zalcitabine
Brand name: Hivid
Adult dose: 0.75 mg q 8

Abbrev: d4T
Generic name: stavudine
Brand name: Zerit
Adult dose: 30-40 mg q 12

Abbrev: 3TC
Generic name: lamivudine
Brand name: Epivir
Adult dose: 150 mg q 12

Chemical name: 1592U89


Protease Inhibitors

Generic name: saquinavir
Brand name: Invirase

Generic name: ritonavir
Brand name: Norvir
Adult dose: 600 q 12*

Generic name: indinavir
Brand name: Crixivan
Adult dose: 800 q 8

Generic name: nelfinavir
Brand name: Viracept

Chemical name: 141W94 (VX 478)

Chemical name: KNI-272

Chemical name: ABT-378


Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

Generic name: nevirapine
Brand name: Viramune

Generic name: delavirdine
Brand name: Rescriptor

Generic name: atevirdine

Generic name: loviride

Chemical name: DMP-266

Chemical name: HBY-097

Chemical name: MKC-442**


Acyclic Nucleotide Analogs

Chemical name: PMPA

Chemical name: PMEA
Generic name: adefovir dipivoxil

Chemical name: GS840

Legend

Bold: FDA-approved for adults

q: every (e.g. 800 mg q 8 means 800 mg every 8 hours)

*: dose escalation is recommended when starting: 300 mg q 12 for 3 days to 400 mg q 12 for 3 days to 500 mg q 12 for 3 days to 600 mg q 12

**: functions as NNRTI although structure is NA

Page last updated 9 April 1997


About AIDS | Treatment | Prevention | Policy | About SFAF | Take Action | Donate
Espaņol | Search | Site Map | Feedback | Email Updates | Home (sfaf.org)